Lundbeck raises 2022 guidance

The Danish pharmaceutical company has just announced that it is raising its financial expectations for the full year due to strong sales momentum for a number of its products. (Updated)

Photo: Jens Dresling

On Tuesday, Danish pharmaceutical firm Lundbeck announced a guidance upgrade, according to a company press release.

Lundbeck says a strong underlying positive momentum for its medicines Abilify Maintena, Brintellix/Trintellix, Rexulti, and Vyepti, in addition to a strong US dollar, have proved enough to warrant new goals for the rest of the year.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

FDA fast-tracks Eli Lilly's obesity candidate

Tirzepatide is already approved for type 2 diabetes, and Lilly has been vying for access to the obesity market for a while – the day the drug could be approved in both indications has now been moved up.

Jefferies spots weaknesses in GN

One potential chink in GN’s armor is that the company’s newly announced hearing aid platform, Omnia, isn’t predicted to win significant market shares.

Further reading

Related articles

Latest news

See all jobs